Glenmark Pharmaceuticals gets USFDA nod for Abiraterone Acetate Tablets; Stock surges 2%

Glenmark Prescription drugs Inc., USA (Glenmark) has obtained ultimate approval by america Meals & Drug Administration (U.S. FDA) for Abiraterone Acetate Tablets USP, 500 mg, the generic model of Zytiga Tablets, 500 mg, of Janssen Biotech Inc.

In keeping with IQVIATM gross sales knowledge for the 12 month interval ending March 2022, the Zytiga Tablets, 500 mg market2 achieved annual gross sales of roughly $260.2 million.

Glenmark’s present portfolio consists of 173 merchandise approved for distribution within the U.S. market and 49 ANDA’s pending approval with the U.S. FDA.

Along with these inner filings, Glenmark continues to establish and discover exterior growth partnerships to complement and speed up the expansion of its present pipeline and portfolio.

At round 10:22 AM, Glenmark Prescription drugs was buying and selling at Rs400.85 apiece up by Rs8.35 or 2.13% from its earlier closing of Rs392.50 apiece on the BSE.